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Community engagement and integrated health and polio 
immunisation campaigns in conflict-affected areas of 
Pakistan: a cluster randomised controlled trial 
Muhammad Atif Habib, Sajid Soofi, Simon Cousens, Saeed Anwar, Najib ul Haque, Imran Ahmed, Noshad Ali, Rehman Tahir, Zulfiqar A Bhutta
Summary
Background Pakistan faces huge challenges in eradicating polio due to widespread poliovirus transmission and 
security challenges. Innovative interventions are urgently needed to strengthen community buy-in, to increase the 
coverage of oral polio vaccine (OPV) and other routine immunisations, and to enhance immunity through the 
introduction of inactivated polio vaccine (IPV) in combination with OPV. We aimed to evaluate the acceptability and 
effect on immunisation coverage of an integrated strategy for community engagement and maternal and child health 
immunisation campaigns in insecure and conflict-affected polio-endemic districts of Pakistan.
Methods We did a community-based three-arm cluster randomised trial in healthy children aged 1 month to 5 years 
that resided within the study sites in three districts of Pakistan at high risk of polio. Clusters were randomly assigned 
by a computer algorithm using restricted randomisation in blocks of 20 by an external statistician (1:1:1) to receive 
routine polio programme activities (control, arm A), additional interventions with community outreach and 
mobilisation using an enhanced communication package and provision of short-term preventive maternal and child 
health services and routine immunisation (health camps), including OPV (arm B), or all interventions of arm B with 
additional provision of IPV delivered at the maternal and child health camps (arm C). An independent team conducted 
surveys at baseline, endline, and after each round of supplementary immunisation activity for acceptability and effect. 
The primary outcome measures for the study were coverage of OPV, IPV, and routine extended programme on 
immunisation vaccines and changes in the proportion of unvaccinated and fully vaccinated children. This trial is 
registered with ClinicalTrials.gov, number NCT01908114.
Findings Between June 4, 2013, and May 31, 2014, 387 clusters were randomised (131 to arm A, 127 to arm B, and 129 
to arm C). At baseline, 28 760 children younger than 5 years were recorded in arm A, 30 098 in arm B, and 29 126 in 
arm C. 359 clusters remained in the trial until the end (116 in arm A, 120 in arm B, and 123 in arm C; with 23 334 children 
younger than 5 years in arm A, 26 110 in arm B, and 25 745 in arm C). The estimated OPV coverage was 75% in arm A 
compared with 82% in arm B (difference vs arm A 6·6%; 95% CI 4·8–8·3) and 84% in arm C (8·5%, 6·8–10·1; overall 
p<0·0001). The mean proportion of routine vaccine doses received by children younger than 24 months of age was 
43% in arm A, 52% in arm B (9%, 7–11) and 54% in arm C (11%, 9–13; overall p<0·0001). No serious adverse events 
requiring hospitalisation were reported after immunisation.
Interpretation Despite the challenges associated with the polio end-game in high-risk, conflict-affected areas of 
Pakistan, a strategy of community mobilisation and targeted community-based health and immunisation camps 
during polio immunisation campaigns was successful in increasing vaccine coverage, including polio vaccine coverage.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Pakistan, Afghanistan, and Nigeria are the only three 
remaining countries with endemic polio.1 Although the 
number of polio cases and their geographical spread 
have reduced, insecurity, poor access to populations, and 
residual pockets of circulating poliovirus in these three 
countries remain an important challenge for global polio 
eradication. Most routine childhood immunisations in 
Pakistan are delivered at fixed immunisation sites, with 
some outreach services through vaccinators; however, 
coverage rates for many routine childhood immunisation 
vaccines remain low, on average between 65% and 
73% for vaccines containing diphtheria, tetanus, and 
pertussis (DTP).2 Oral polio vaccine (OPV) is delivered 
differently. Although routine childhood immunisation 
services should provide four doses of OPV (at birth, 6, 10, 
and 14 weeks of age), repeated, concerted door-to-door 
immunisation campaigns, called supplementary immun-
isation activities, have been used to try to increase OPV 
coverage.3 The supplementary immunisation activities 
are household-level campaigns organised by the Pakistan 
national polio programme and usually last 5 days (3 days 
to visit all households, with 2 days for return visits to 
households with initially absent or missed children with 
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door-to-door OPV administration to children younger 
than 5 years of age by health workers. These children 
have their fingers marked using permanent ink for ease 
of identification in post-vaccination mop-up activities 
and surveys. Supplementary immunisation activities 
have been particularly challenging in parts of the country 
affected by insurgency and insecurity, with groups 
such as the Taliban limiting access to populations,4 
disinformation leading to refusal of OPV,5 and attacks 
targeting polio workers.6 In particular, in the high-risk 
areas of northwest Pakistan and several slums of Karachi, 
polio workers have been subjected to several attacks and 
assassinations, with bans imposed on polio vaccination 
activities by the Pakistani Taliban and other extremist 
groups, as well as general insecurity impeding the access 
of polio programme teams to such communities.7 
These barriers to the polio programme activities are 
compounded by inefficiencies within the routine child-
hood immunisation programme, the poor state of 
environmental sanitation, and high burdens of childhood 
diarrhoea and malnutrition, which make transmission 
more probable and potentially impair the response to 
OPV.8–10 An important issue in many areas is insufficient 
community buy-in for the polio-focused supplementary 
immunisation activities and general fatigue with the 
repeated rounds of house hold OPV administration 
(estimated to have exceeded 150 rounds to date).
These issues were brought to the fore by a massive 
upsurge in polio cases in Pakistan (rising from 58 cases 
in 2012, to 93 cases in 2013, and to 306 cases in 2014; 
appendix). Additionally, the country faced the challenge 
of introducing the inactivated polio vaccine (IPV) with 
the third dose of DTP vaccine (DTP3), as recommended 
by the WHO Strategic Advisory Group of Experts (SAGE) 
committee for vaccines.11 The recommendation seeks to 
address the risk of emergence of circulating vaccine-
derived polioviruses (cVDPV), typically cVDPV2, OPV 
virus type 2, and the co ordinated withdrawal of trivalent 
OPV and its replacement by bivalent OPV.12 This 
recommendation to introduce IPV was based on evidence 
from studies documenting enhanced serum antibody 
response and improved mucosal immunity with a 
Research in context 
Evidence before this study
We did a systematic review of available information about 
strategies for addressing polio eradication in conflict and 
insecurity settings using the broad terms “polio” and 
“vaccination strategies”, and MeSH terms “insecurity”, “war”, 
and “conflict”. The search encompassed Jan 1, 2000, to Dec 
31, 2016, and was not restricted to the English language. Our 
review did not identify any randomised controlled trials or 
systematic reviews of immunisation strategies addressing polio 
programme refusals or insecurity. We assessed a large number of 
reports documenting the temporal association between conflict, 
insecurity, and risks to polio eradication, as well as re-emergence 
of polio. These issues have been compounded in the past 
5–6 years by attacks on polio and health workers and insecurity 
had been documented as an important barrier to polio 
eradication activities in conflict settings. In other instances, 
negative propaganda by some religious factions and 
obscurantists have affected population uptake of oral polio 
vaccine (OPV) and led to refusals. Although a combination of 
approaches has been suggested to circumvent these issues, the 
scientific basis for community-based approaches in such 
settings is very limited. A Cochrane review of strategies to scale 
up childhood immunisations also did not present any 
information from studies done in such conflict settings or 
insecure contexts. Barring one report of mass immunisation in 
northern Nigeria and other approaches using the military in 
Angola, we identified no reports of evaluations of strategies to 
scale up polio or routine immunisations in conflict settings. A 
systematic review of service delivery platforms for maternal, 
newborn, and child health strategies in Pakistan did not identify 
a study of routine immunisations or polio-associated 
interventions.
Added value of this study
To our knowledge, our study is the first scientifically designed 
formal evaluation of a community-based strategy to approach 
high-risk populations in conflict-affected and insecure 
populations with an integrated package of maternal and child 
health and immunisation services delivered during routine 
polio campaigns. The results indicated widespread acceptance, 
with more than two-thirds of target children and families in 
these districts accessing these short-term fixed camps during 
the 4 days of the campaigns. Contrary to initial fears, the 
coverage of OPV increased 8·5% overall, uptake of inactivated 
polio vaccine administered alongside OPV was high, and the 
number of children who were not immunised was reduced 
overall.
Implications of all the available evidence
Our findings strongly support the adaptation of comparable 
community-based integrated strategies for community 
engagement, grass-root mobilisation, and integration of 
polio, routine immunisation, and maternal and child health 
services in the residual high-risk population reservoirs with 
circulating poliovirus in Pakistan and the conflict-affected 
bordering areas with Afghanistan. These strategies can be 
integrated with routine health and immunisation services. 
Our findings suggest that engaging local community 
members and political leaders is important to secure access 
and community buy-in. A historical review of the political 
determinants of polio in five countries affected by Islamist 
militancy also concluded that rather than military victory 
against the militants, securing local de-facto political support 
was crucial for success.
See Online for appendix
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combination of OPV and IPV compared with OPV alone, 
resulting in a substantial reduction in poliovirus 
excretion,13–15 and protecting the population ahead of the 
withdrawal of trivalent OPV vaccine. The bivalent OPV 
was introduced in Pakistan in April, 2016.
Given the limited vaccine coverage of the routine 
childhood immunisation programme, the context of 
insecurity, and limited community engagement in some 
populations, introduction of IPV into the national polio 
eradication strategies in Pakistan posed numerous 
challenges. In addition to the obvious questions around 
the probable IPV coverage rates in view of low coverage 
rates of routine childhood immunisation vaccines, 
especially DTP3, key concerns were raised about the 
possible negative consequences of IPV introduction 
for the acceptance and coverage of the existing OPV pro-
gramme, especially in areas where refusals of OPV were 
noted within supplementary immunisation activities.
We hypothesised that in these insecure polio-endemic 
areas of Pakistan with poorly functioning routine 
childhood immunisation systems, a strategy of enhanced 
community engagement together with the provision of 
some maternal, child health, and immunisation services 
in time-limited camps alongside planned supplementary 
immunisation activities would enhance overall OPV 
coverage. We also hypothesised that this might be a useful 
mechanism for introducing IPV and enhancing its 
acceptability in such populations. We aimed to evaluate 
the effect on vaccine coverage of this enhanced maternal, 
child health, and immunisation service package, with or 
without additional IPV, delivered through health camps 
alongside the regular polio supplementary immunisation 
activities.
Methods
Study design and participants
We did this community-based, three-arm cluster 
randomised trial in three geographical areas in Pakistan 
reported as high risk for polio by WHO (figure 1). These 
areas were also selected for risks of ongoing insurgency 
(Bajaur and Karachi) and general insecurity (Kashmore). 
Healthy children aged 1 month to 5 years who lived within 
the study sites, and who did not plan to travel away during 
entire the study period, were eligible for the study. 
Children with known thrombocytopenia or bleeding 
disorders, who were acutely ill or with signs of acute 
Figure 1: Map of Pakistan showing study areas
FATA=Federally Administered Tribal Areas. KPK=Khyber Pakhtunkhwa. AJK=Azad Jammu and Kashmir.
Country boundary
Province boundary
District boundary
Study area
Sindh
Punjab
Azad Jammu and Kashmir
Khyber Pathtunkhwa
Bajaur
Tehsil Khar
Tehsil Mamund
Tehsil Salarzai
Tehsil Utmankhel
Tehsil Barang
Tehsil Nawagai
Kashmore
Union council Kashmore 1 and 2
Union council Kandhkot 2, 3, and 4
Union council Malir
Union council Gulwali
Union council Dolatpur
FATA
Balochistan
Gilgit
Karachi
Gadap Town
Union council 5-Songal
Union council 8-Manghopir
Gulshan Town
Union council 10-Pehelwan Goth
Union council 13-Safoorah Goth
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infection (eg, fever ≥38 °C) at the time of supplementary 
immunisation activity, or who had a diagnosis or 
suspicion of immunodeficiency disorder were not eligible. 
We did a baseline census in the three study areas to 
collect demographic, socioeconomic, routine immun-
isation, and health-seeking data. The baseline census was 
done by locally recruited and trained data collection 
teams, strictly independent of the implementing teams, 
for 3 months. A structured questionnaire was developed 
for the purpose and was pretested on 50 households from 
a locality not included in the trial but having similar 
sociodemographic conditions (appendix). Double data 
entry and cleaning were done concurrently.
The ethics review committee of Aga Khan University 
and the National Bioethics Committee granted approval 
of the trial. In view of the importance of introduction of 
IPV through the existing immunisation programme 
without posing any risks to the existing OPV delivery 
strategy, we devoted considerable time to achieving 
consensus among all national and provincial stakeholders. 
During the inception phase, between October, 2012, and 
June, 2013, a series of consultative meetings at provincial, 
national, and international levels were held, resulting in 
formal approval by the authorities. Life and injury 
insurance for all participants and staff involved in the trial 
and institutional indemnification were also provided; 
because no insurance company in Pakistan was prepared 
to provide this cover, it was secured from an overseas 
insurance company (Aon Insurance Managers, 
Singapore). Individual level consent was taken from the 
parent of the participating child.
Randomisation and masking
A computer algorithm was used to perform restricted 
randomisation in blocks of 20 by matching the population 
size, socioeconomic status, OPV coverage, and extended 
programme on immunisation (EPI) coverage, to assign 
(1:1:1) eligible clusters to three groups. An individual 
cluster was defined as the area assigned to a team for 
polio vaccination during supplementary immunisation 
activities. Arm A (control) received the routine 
im mu ni sation package and additional OPV in 
supplementary immunisation activities (no special 
measures such as short message service messages, 
posters, banners, or mass media promotions were 
employed in these areas). Arm B received additional 
interventions with community outreach and mobilisation 
using an enhanced com munication package, and 
provision of maternal and child health immunisation 
services through low-cost health camps established to run 
from day 4 of polio supplementary immunisation 
activities. The clusters in arm C received the same 
intervention package as arm B with the addition of IPV 
(Imovax, Sanofi Pasteur, Lyon, France) delivered at the 
maternal and child health immunisation strategy camps. 
The trial was designed to cover four consecutive 
supplementary immunisation activity rounds over 
12 months, with IPV administered in rounds one and 
three, while the community mobilisation activities 
continued throughout the duration of the project. An 
independent team conducted baseline, end line and post-
supplementation immunisation strategy surveys at the 
end of each round (appendix). Because of the nature of 
the intervention, trial investigators were not masked. The 
main trial statistician (SC) was not involved in field 
implementation. 
Procedures
A community mobilisation plan and information, 
education, and communication (IEC) materials—
specifically a pictorial booklet and counselling cards—
were prepared during the inception phase and ratified by 
all relevant stakeholders. The IEC materials contained 
information on maternal health, nutrition, hygiene and 
sanitation, immunisation, polio, and health camps. 
Figure 2: Trial profile
387 clusters randomised
 131 clusters 
21 242 households visited
 1305 locked
 429 refused
 19 508 completed
28 760 children <5 years
 127 clusters 
21 348 households visited
 1030 locked
 315 refused
 20 003 completed
30 098 children <5 years
129 clusters 
21 324 households visited
 1193 locked
 348 refused
 19 783 completed
29 126 children <5 years
 116 clusters 
17 500 households visited
 2016 locked
 293 refused
 15 191 completed
23 334 children <5 years
 120 clusters 
190 974 households visited
 2015 locked
 330 refused
 17 629 completed
 26 110 children <5 years
 123 clusters
20 093 households visited
 2255 locked
 3238 refused
 17 600 completed
25 745 children <5 years
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Teams of two female and one male community mobilisers 
were recruited and trained to deliver the information 
contained in the IEC material and were provided with an 
IEC booklet and counselling cards as job aids. Each team 
covered four clusters and delivered these key messages 
through individual sessions with parents and group 
sessions with male groups, female groups, and health-
care providers at cluster level. Sessions with community 
and religious leaders, teachers, and other prominent 
persons were done at union council level. Typically ten to 
20 people attended the male and female group sessions; 
five to ten attended the others. The sessions with health-
care providers and influencers were limited to the 
introduction of the project, with a focus on the 
importance of routine immunisation and OPV 
administration (and IPV use as relevant to the specific 
clusters). We also provided information regarding 
maternal health, nutrition, hygiene and sanitation, 
immunisation, and polio during sessions with female 
members of the community. Although the study team 
did not make direct contact with local militant leaders 
and Taliban commanders, community elders were 
closely consulted who might have communicated with 
such individuals.
The community mobilisation teams also promoted 
health camps offering maternal and child health 
immunisation services during the scheduled supplemen-
tation immunisation strategies, including missed OPV 
doses. Promotion was limited to provision of information 
regarding services being offered at health camps and 
encouraging use of those services Additional information 
about the availability of IPV for coadministration with 
OPV (as needed) in the health camps was only provided 
in clusters of arm C. This strategy was agreed with the 
national polio programme to prevent any disinformation 
about the existing OPV strategy. Based on instructions 
from the health department, no large-scale public 
dissemination was undertaken regarding IPV use and 
availability. To avoid potential contamination between 
arms, the community mobilisation teams informing 
communities in arms B and C about health camps also 
provided colour-coded invitation cards required for 
visiting the health camps, and vaccine allocation 
(additional IPV) was made as per the colour codes. 
Details of community mobilisation sessions conducted 
across sites and arms are in the appendix.
During each of the four supplementary immunisation 
activity rounds, approximately 60 maternal and child 
health and immunisation camps were held in clusters 
of arms B and C. The camps generally started on the 
fourth day of supplementary immunisation activities, 
lasted for 3–4 days, and covered two adjacent clusters. 
They were open for 7–8 h per day. In addition to the 
fixed main camps, a few mobile camps were also 
organised in some remote clusters to improve 
community access as needed. Each health camp was 
staffed by one supervising medical officer, 
one vaccinator, one paramedic, and two facilitators. 
Staff provided counselling on hygiene, nutrition, and 
routine immunisations and undertook general 
maternal and child health assessments. The health 
camp staff were trained to provide standard medical 
care, follow good clinical practices, maintain a strict 
cold chain, and follow safe injection practices. The 
health-care providers in the camps delivered nutrition 
interventions such as micronutrient supplements, 
routine immunisations, and OPV as needed. Written 
consent was obtained for IPV administration because it 
was not included in routine immunisation vaccines at 
that time. Primary care medications for common 
illnesses were admin istered as per WHO and 
Control (arm A; 
n=28 760)
Community mobilisation 
and health camps (arm B; 
n=30 098)
Community mobilisation 
and health camps with IPV 
(arm C; n=29 126)
Children <5 years old
Karachi 7415 (26%) 7579 (25%) 7310 (25%)
Bajaur 11 705 (41%) 12 481 (41%) 11 995 (41%)
Kashmore 9640 (34%) 10 038 (33%) 9821 (34%)
Sex
Female 13 787 (48%) 14 341 (48%) 13 926 (48%)
Male 14 973 (52%) 15 757 (52%) 15 200 (52%)
Age (months)
0–5 2032 (7%) 2113 (7%) 2052 (7%)
6–11 2493 (9%) 2493 (8%) 2474 (8%)
12–23 4646 (16%) 4907 (16%) 4761 (16%)
24–59 19 589 (68%) 20 585 (68%) 19 839 (68%)
Access to improved water source*
No 3517 (12%) 5339 (18%) 4398 (15%)
Yes 25 243 (88%) 24 759 (82%) 24 728 (85%)
Access to a latrine
No 7114 (25%) 6946 (23%) 7123 (24%)
Yes 21 646 (75%) 23 152 (77%) 22 003 (76%)
Vaccination card available
No 25 050 (87%) 26 024 (86%) 25 209 (87%)
Yes 3710 (13%) 4074 (14%) 3917 (13%)
Immunisation status†
Full 6280 (22%) 6499 (22%) 6379 (22%)
Partial 10 259 (36%) 10 916 (36%) 10 566 (36%)
No routine EPI 12 221 (42%) 12 683 (42%) 12 191 (42%)
Received OPV during last campaign
No 5540 (19%) 5656 (19%) 5408 (19%)
Yes 23 220 (81%) 24 442 (81%) 23 718 (81%)
Received vitamin A during last campaign‡
No 5156 (19%) 5342 (19%) 3767 (14%)
Yes 21 572 (81%) 22 643 (81%) 23 307 (86%)
IPV=inactivated polio vaccine. EPI=expanded programme on immunisation. OPV=oral polio vaccine. *Improved source 
includes government tap, well, or hand pump; bottled water or mineral water; own tap, well, or hand pump; and 
borehole. †Fully immunised defined as child has received all routine immunisation antigens for his age; partially 
immunised defined as the child is not fully immunised; and no routine immunisation defined as the child did not 
receive any routine immunisation antigen. ‡Of children aged 6 months or older at baseline.
Table 1: Baseline sociodemographic characteristics and immunisation status of children younger than 
5 years and their families
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Government of Pakistan guidelines.16 Children 
receiving IPV were monitored for any adverse reaction 
for 30 min after vaccination. Camp medical officers 
provided a contact number for parents to call in the 
event of any delayed adverse effect of IPV or other 
injectable vaccines.
Based on the baseline census data, cluster-specific 
vaccine record books were prepared. These books 
contained details of children falling in the target age 
range for vaccination and were used to record information 
regarding vaccination at the health camps for these 
children. Vaccination records for children who were born 
after the census and were vaccinated at health camps 
were also recorded in the vaccine record books.
At every stage of the project, strict monitoring and 
supervision was undertaken by both internal and external 
monitors using checklists. Monitoring supervisors 
conducted surprise visits to check the project activities 
and refresher trainings were given to the community 
mobilisation and health camp teams on the basis of their 
recommendations.
We established five independent mobile data collection 
teams of three people per union council or tehsil to do 
surveys after the vaccination rounds on a subset of 
households in each cluster to assess OPV and IPV 
coverage. A list of 25–30 households was computer-
generated by the data management unit for each cluster 
from the existing sampling frame. Within a week of 
completion of supplementary immunisation activities 
and conclusion of camps in arms B and C, the data 
collection teams visited the targeted clusters, identified 
each household on the list, and, after verbal informed 
consent, obtained information on OPV or IPV uptake 
and source from the caregiver of the child.
After four supplementary immunisation activity 
rounds, an end-line census was performed in all clusters 
to assess the change in routine immunisation coverage, 
OPV coverage, and the acceptability of IPV using the 
same structured questionnaire as for the baseline survey 
(appendix).
Outcomes
The primary outcome measures for the study were 
coverage of OPV, IPV, and routine EPI vaccines and 
changes in the proportion of unvaccinated and fully 
vaccinated children between baseline and end-line 
surveys. The original trial protocol also included a 
primary endpoint of the prevalence of serum neutralising 
antibodies to all three types of poliovirus in arm B versus 
arm C, but the risks associated with blood sampling in 
this region were considered too great to rely on this as a 
main trial outcome. When registering the trial, we 
therefore included this as a secondary endpoint, along 
with estimation of stool shedding of poliovirus and 
environmental sampling for poliovirus circulation. These 
results will be reported separately. 
Statistical analysis
We estimated that a sample size of 40 clusters per arm 
per geographical study site with 150 children per cluster 
would provide greater than 90% power to detect an 
increase in OPV coverage from 80% to 95% in a given 
site at the 5% level of significance and a coefficient of 
variation of 0·14. Across the three sites, an overall 
sample size of 120 clusters per arm with an average of 
150 children per cluster, would provide 90% power to 
detect an increase in OPV coverage from 80% to 85%.17 
To estimate the sample size for the sequential surveys 
of coverage estimates after supplementary 
immunisation activity, a conservative OPV coverage of 
80% with a 5% increase was assumed. A sample size of 
Karachi Bajaur Kashmore
Community 
mobilisation 
and health 
camps 
(arm B)
Community 
mobilisation 
and health 
camps and 
IPV (arm C)
Community 
mobilisation 
and health 
camps 
(arm B)
Community 
mobilisation 
and health 
camps and 
IPV (arm C)
Community 
mobilisation 
and health 
camps 
(arm B)
Community 
mobilisation 
and health 
camps and 
IPV (arm C)
Children at 
baseline
7579 7310 12 481 11 995 10 038 9821
BCG
1 51 46 153 287 232 260
2 91 91 229 245 220 238
3 89 46 263 255 238 258
4 94 29 265 274 250 206
Total 325 212 910 1061 940 962
OPV
1 458 367 816 1087 1224 1155
2 674 358 977 902 1310 1449
3 625 335 939 1016 1327 1456
4 623 408 1112 1197 1257 1327
Total 2380 1468 3844 4202 5118 5387
Pentavalent
1 290 572 619 695 826 727
2 251 242 626 576 737 1138
3 227 248 646 754 912 1144
4 267 273 564 982 881 1124
Total 1035 1335 2455 3007 3356 4133
Measles
1 264 433 490 495 597 806
2 542 616 303 451 778 586
3 111 153 422 415 129 172
4 978 1040 325 356 447 320
Total 1895 2242 1540 1717 1951 1884
IPV
1 NA 5851 NA 7431 NA 8469
2 NA NA NA NA NA NA
3 NA 6344 NA 8318 NA 9102
4 NA NA NA NA NA NA
Total NA 12 195 NA 15 749 NA 17 571
IPV=inactivated polio vaccine. OPV=oral polio vaccine. NA=not applicable. 
Table 2: Numbers of vaccine doses delivered at health camps
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3048 per site (rounded to 3050) was estimated, 
assuming a design effect of 2, to provide 80% power at 
the 5% level of significance with 5% attrition. The 
estimate was revised to 3619 (rounded to 3600) after the 
first round using 20% attrition to account for non-
response.
All data were double-entered using Visual FoxPro and 
backed up at the data management unit at Aga Khan 
University, with hard copies archived and stored at the 
institution’s data repository. Demographic, clinical, and 
vaccination data were merged and analysed using Stata 
(versions 12 and 14). We calculated area and round-specific 
vaccination coverage for all arms across baseline, surveys 
after supplementary immunisation activities, and end-line 
surveys. We analysed vaccination coverage using a 
generalised linear model with the binomial probability 
model and identity link function to produce estimates of the 
percentage point difference in coverage between arms. We 
accounted for the clustered nature of the data using Taylor-
linearised variance estimates with the three study areas 
treated as strata and the randomised clusters as primary 
sampling units. The number of doses administered was the 
count of all doses of OPV, IPV, and EPI vaccines actually 
given excluding unused doses and wastage. 
This trial is registered with ClinicalTrials.gov, number 
NCT01908114.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication. 
Results
Between June 4, 2013, and May 31, 2014, 387 clusters were 
randomised (131 to arm A, 127 to arm B, and 129 to 
arm C). At baseline, 28 760 children younger than 5 years 
were recorded in arm A, 30 098 in arm B, and 29 126 in 
arm C. 359 clusters remained in the trial until the end 
(116 in arm A, 120 in arm B, and 123 in arm C; with 
23 334 children younger than 5 years in arm A, 26 110 in 
arm B, and 25 745 in arm C; figure 2).
Baseline sociodemographic characteristics of enrolled 
children and their families were similar (table 1) but with 
slightly poorer access to an improved water source in 
arm B. Few children (13%) had vaccination cards available 
and 42% of children were reported to have received no 
routine EPI vaccination at all. Most children (81%) were 
reported to have received OPV during the last round of 
supplementary immunisation activity and a similar 
proportion was reported to have received vitamin A drops 
during the preceding 6 months.
Control (Arm A) Community mobilisation and health 
camps (arm B)
Community mobilisation and health 
camps and IPV (arm C)
p value*
Estimated coverage Estimated coverage Coverage difference 
(95% CI)
Estimated coverage Coverage difference 
(95% CI)
Round 1
Karachi 63% (53 to 71) 81% (74 to 87) 18·6% (7·2 to 30·1) 75% (66 to 82) 12·3% (–0·2 to 24·9) 0·0072
Bajaur 77% (74 to 80) 79% (77 to 82) 1·9% (–1·9 to 5·7) 81% (78 to 83) 3·5% (–0·4 to 7·4) 0·21
Kashmore 72% (73 to 74) 76% (74 to 78) 3·7% (1·0 to 6·4) 78% (76 to 80) 5·4% (2·9 to 7·9) 0·0002
Total 71% (68 to 74) 78% (76 to 80) 6·6% (3·5 to 9·7) 78% (76 to 80) 6·6% (3·4 to 9·8) <0·0001
Round 2
Karachi 72% (65 to 79) 80% (74 to 84) 7·4% (–1·4 to 16·2) 84% (80 to 88) 12·0% (3·8 to 20·1) 0·0142
Bajaur 76% (73 to 78) 83% (80 to 85) 6·9% (3·4 to 10·1) 84% (81 to 86) 7·7% (4·3 to 11·2) <0·0001
Kashmore 75% (72 to 77) 80% (77 to 82) 5·2% (2·2 to 7·0) 82% (78 to 84) 7·0 (3·5 to 10·4) 0·0001
Total 75% (73 to 76) 81% (79 to 83) 6·2% (3·6 to 8·8) 83% (81 to 85) 8·4% (5·8 to 11·0) <0·0001
Round 3
Karachi 77% (67 to 84) 82% (78 to 86) 5·5% (–4·0 to 14·9) 88% (84 to 90) 10·8% (1·9 to 19·8) 0·0167
Bajaur 77% (75 to 80) 86% (84 to 88) 8·3% (5·5 to 11·1) 87% (84 to 89) 9·2% (5·4 to 13·0) <0·0001
Kashmore 79% (75 to 82) 82% (81 to 84) 3·6% (0·0 to 7·2) 85% (83 to 86) 5·8% (2·2 to 9·5) 0·0054
Total 78% (75 to 80) 83% (82 to 85) 5·3% (2·3 to 8·2) 86% (84 to 87) 7·9% (5·0 to 10·8) <0·0001
Round 4
Karachi 73% (68 to 77) 82% (74 to 87) 8·6% (1·1 to 16·1) 86% (83 to 89) 13·1% (7·8 to 18·5) <0·0001
Bajaur 81% (78 to 83) 88% (86 to 90) 6·9% (3·8 to 10·0) 90% (88 to 91) 8·6% (5·6 to 11·7) <0·0001
Kashmore 76% (74 to 78) 86% (84 to 87) 9·5% (6·9 to 12·2) 87% (85 to 89) 11·1% (8·3 to 13·9) <0·0001
Total 77% (75 to 79) 85% (83 to 87) 8·3% (6·0 to 10·6) 88% (86 to 89) 10·7% (8·7 to 12·6) <0·0001
Overall (all sites, all rounds) 75% (74 to 77) 82% (81 to 83) 6·6% (4·8 to 8·3) 84% (83 to 85) 8·5% (6·8 to 10·1) <0·0001
OPV=oral polio vaccine. *Testing the null hypothesis of no differences in coverage across the three arms. Numbers in parantheses are 95% CI.
Table 3: OPV coverage during each round of supplementary immunisation activities
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The number of vaccine doses delivered at health camps 
held during each of the four supplementary immunisation 
activity rounds are shown in table 2. 23 343 children 
received 53 359 doses of routine immun isations (includ-
ing 22 399 OPV doses). 26 867 children younger than 
5 years also received 45 515 doses of IPV at the maternal 
and child health and immunisation camps. No health 
camps were held in the control arm (arm A). No serious 
adverse events requiring hospitalisation were reported 
after immunisation. There were some events of fever and 
pain at the site of injection that were treated either at 
health camps or the study team.
Across all four rounds, the average estimated coverage 
of OPV was 75% (95% CI 74–77) in arm A, 82% (81–83%) 
in arm B, and 84% (95% CI 83–85%) in arm C 
(overall p<0·0001; table 3). On average, across rounds, 
coverage was 6·6 percentage points (95% CI 4·8–8·3) 
higher in arm B than in arm A and 8·5 percentage points 
(6·8–10·1) higher in arm C than in arm A. A consistent 
pattern across sites and across rounds was observed of 
higher coverage in the two intervention arms (B and C) 
than in control arm (arm A; figure 3).
The proportion of unvaccinated children according to 
the routine childhood immunisation schedule was 42% 
in each arm at baseline (table 4). At end line, this 
proportion was reduced to 36% (95% CI 32–41%) in 
arm A, 28% (95% CI 24–31) in arm B, and 27% (24–31) in 
arm C. Similarly the proportion of fully vaccinated 
children was about 22% at baseline in all three arms. At 
end line, this proportion had increased to 25% (22–28) in 
arm A, 32% (29–35) in arm B, and 34% (31–37) in arm C. 
A consistent pattern was seen across sites. The proportion 
of fully vaccinated children increased in the 
two intervention arms compared with the control arm 
(7·3% [95% CI 4·5–10·0] increase in arm B vs arm A; 
9·5% [6·9–12·0] increase in arm C vs arm A; overall 
p<0·0001).
The mean proportion of routine childhood 
immunisation doses that each child received was 39% 
(36–42) in all three arms at baseline and increased to 43% 
(40–45) in arm A, 52% (49–55) in arm B, and 54% (51–57) 
in arm C at end line (table 5). The proportion of vaccine 
doses received increased in all three sites. Children in 
Karachi received, on average, a higher proportion of 
Figure 3: OPV coverage by rounds
OPV=oral polio vaccine. IPV=inactivated polio vaccine.
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Control (arm A) Community mobilisation and health 
camps (arm B)
Community mobilisation and health 
camps and IPV (arm C)
Baseline End line Baseline End line Baseline End line
Karachi
Not immunised 30% (24–36) 25% (21–29) 27% (22–34) 16% (12–21) 25% (21–31) 11% (9–13)
Partially immunised 29% (26–32) 26% (24–30) 29% (27–32) 30% (27–33) 33% (31–35) 34% (30–38)
Fully immunised 41% (36–46) 49% (44–53) 43% (37–49) 54% (48–60) 41% (37–46) 56% (51–61)
Bajaur
Not immunised 62% (59–66) 60% (57–62) 63% (59–67) 47% (45–49) 64% (61–68) 48% (46–50)
Partially immunised 23% (19–27) 22% (19–25) 23% (19–28) 27% (25–29) 21% (17–26) 25% (23–28)
Fully immunised 15% (14–16) 19% (17–20) 14% (13–16) 26% (24–28) 14% (13–16) 26% (25–28)
Kashmore
Not immunised 29% (23–35) 19% (14–25) 27% (22–34) 16% (12–21) 26% (21–33) 17% (13–21)
Partially immunised 56% (49–63) 64% (57–71) 58% (51–65) 62% (54–69) 57% (50–64) 56% (49–63)
Fully immunised 15% (12–20) 17% (13–21) 14% (11–19) 22% (17–27) 17% (13 –21) 27% (22–32)
All sites combined
Not immunised 42% (38–47) 36% (32–41) 42% (38–47) 28% (24–31) 42% (38–46) 27% (24–31)
Partially immunised 36% (32–40) 39% (34–45) 36% (32–41) 40% (36–45) 36% (32–40) 39% (35–43)
Fully immunised 22% (19–25) 25% (22–28) 22% (19–24) 32% (29–35) 22% (19–25) 34% (31–37)
EPI=expanded programme on immunisation. IPV=inactivated polio vaccine. Numbers in parantheses are 95% CI.
Table 4: Vaccination status of children according to routine EPI schedule
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vaccine doses than children in the other two sites. The 
percentage point increase in the proportion of scheduled 
vaccine doses received by the children versus the control 
arm A, was estimated to be 9% (95% CI 7–11) for arm B 
and 11% (9–13) for arm C (table 6).
The estimated coverage from post-vaccination surveys 
of IPV in round 1 in arm C was 86·3% (95% CI 
81·7–89·9) for Karachi, 90·0% (87·4–92·2) for Bajaur, 
and 95·9% (93·6–97·3) for Kashmore. The estimated 
coverage from post-vaccination surveys of IPV in round 3 
in arm C was 93·2% (89·9–95·5) for Karachi, 86% 
(82·6–88·6) for Bajaur, and 98·6% (97·3–99·3) for 
Kashmore in round 3 (table 7). Coverage with IPV in 
arm C was higher than that with OPV at both rounds 
(1 and 3) at which it was administered (greater than 85% 
at both rounds across all three areas; table 7).
Completeness of post-supplementary immunisation 
surveys was consistently very high in Kashmore and, 
with the exception of round 1 in control arm, in Bajaur as 
well (appendix). Completeness in Karachi was 
consistently lower than the other two sites but still 
reasonably high with the exception of round 2. The low 
coverage in survey completeness in round 1 of Bajaur 
and round 2 of Karachi reflects problems of accessibility 
due to the operations by security forces in some of the 
areas.
Data for the reasons for non-receipt of OPV and IPV 
were also collected during the surveys (appendix). For 
OPV, the most common reasons for non-receipt were 
that the team did not visit and the child was away at the 
time of the supplementary immunisation activities and 
this pattern was consistent across arms, rounds, and 
sites. For IPV, the most common reason for non-receipt 
was the child being away from the area; the proportion of 
refusals across sites was much lower for IPV than for 
OPV, with some safety concerns largely restricted to 
Karachi (appendix).
Discussion
The results of our study showed that, despite insecurity 
due to militancy, and hesitancy in receiving OPV doses at 
home during supplementary immunisation activities, 
an innovative approach of community mobilisation 
combined with delivery of maternal and child health and 
immunisation interventions through temporary health 
camps during supplementary immunisation activities 
was effective in increasing coverage of OPV and other 
childhood vaccines in Pakistan. Furthermore, the high 
coverage achieved with IPV in intervention arm C 
suggested that the strategy of delivering IPV alongside 
OPV and other vaccines through fixed health camps is 
both feasible and acceptable. The interventions were 
well accepted, with the health camps accessed by families 
with more than 50 000 child visits. The strategy of 
delivering IPV with maternal and child health and 
immunisation services resulted in an estimated IPV 
coverage of about 80% with an excellent safety profile. 
Contrary to concerns expressed about the possible 
negative effects of IPV availability and administration on 
OPV acceptance and uptake, coverage of OPV was 
8·5 percentage points higher in the intervention arm 
that also delivered IPV than in the arm that only delivered 
OPV. Given the challenges associated with the polio 
programme in Pakistan, this increase in OPV coverage is 
important in achieving the threshold needed for stopping 
Control (arm A) Community mobilisation and health camps (arm B) Community mobilisation and health camps and IPV (arm C)
Baseline End line Baseline End line Baseline End line
Karachi 59% (53 to 65; 7415) 60% (57 to 64; 5193) 61% (54 to 67; 7579) 70% (65 to 76; 7090) 61% (56 to 66; 7310) 74% (70 to 78; 6640)
Bajaur 28% (26 to 30; 11 705) 32% (30 to 33; 9069) 27% (25 to 29; 12 481) 42% (40 to 44; 9641) 26% (24 to 28; 11 995) 41% (40 to 43; 9576)
Kashmore 38% (34 to 42; 9640) 43% (40 to 47; 9072) 37% (33 to 41; 10 038) 52% (49 to 56; 9529) 39% (34 to 43; 9821) 52% (49 to 56; 9529)
All sites combined 39% (36 to 42; 28 760) 43% (40 to 45; 23 334) 39% (36 to 42; 30 098) 52% (49 to 55; 26 110) 39% (36 to 42; 29 126) 54% (51 to 57; 25 745)
Data are mean percentage (95% CI; n). EPI=expanded programme on immunisation. IPV=inactivated polio vaccine. *58% means that on average children had received 58% of their scheduled EPI vaccinations.
Table 5: Mean proportion*
 
of scheduled EPI vaccine doses actually received, by study site and arm
Control 
(arm A)
Community 
mobilisation and 
health camps (arm B)
Community 
mobilisation and health 
camps and IPV (arm C)
Test of null 
hypothesis that 
neither intervention 
has any effect
Karachi 0 (control) 13% (10–16) 17% (14–20) p<0·0001
Bajaur 0 (control) 10% (8–12) 10% (9–12) p<0·0001
Kashmore 0 (control) 5% (1–10) 9% (4–13) p=0·0003
All sites combined 0 (control) 9% (7–11) 11% (9–13) p<0·0001
Data are the difference in the proportion of EPI vaccine doses received in arms B and C compared with arm A. Numbers 
in parantheses are 95% CI. EPI=extended programme on immunisation. IPV=inactivated polio vaccine. 
Table 6: Effect of interventions on proportion of scheduled EPI vaccinations received among children 
aged <24 months
Round 1 Round 3
Karachi 86·3% (81·7–89·9) 93·2% (89·9–95·5)
Bajaur 90·0% (87·4–92·2) 86·0% (82·6–88·8)
Kashmore 95·9% (93·6–97·3) 98·6% (97·3–99·3)
All sites combined 92·2% (90·6–93·6) 94·3% (93·0–95·3)
Data are estimated mean coverage (95% CI). IPV=inactivated polio vaccine.
Table 7: IPV coverage by site for arm C
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poliovirus circulation. The proportion of fully vaccinated 
children was also increased. 
The success and coverage gains in our trial occurred 
before the initiation of military operations against 
the Taliban and other militant groups in Federally 
Administered Tribal Areas (FATA) and inaccessible areas 
of Karachi.18 The community participation and acceptance 
of the intervention reflected the widespread unmet needs 
for maternal and child health and immunisation services 
in these areas. In fact, the community mobilisation and 
advocacy strategies focused on promoting general 
maternal and child health and immunisations without 
the singular focus on polio vaccination. Our findings 
support the hypothesis that the provision of polio 
vaccines as part of a package of health services might be 
a better way to engage local communities and religious 
leaders than a polio-specific programme.19 Nigeria has 
made good progress in reaching difficult populations 
using a broadly comparable approach,20 although polio 
has re-emerged after 2 years.21 Nevertheless, the situation 
is much improved compared with a few years ago.
Our study had considerable challenges in execution. 
First, at times due to the high demand for services at the 
health camps, it was difficult for project staff to control 
the crowds that turned out. To counter this, we used the 
community leaders and local community volunteers for 
support. Second, observation of vaccinators revealed 
some errors in injection technique during the first 
round—highlighting the need for appropriate training of 
vaccinators and supervisors. Fortunately, this was not 
associated with any serious adverse events but was a 
major source of anxiety for national polio programme 
managers and local political leadership in FATA where 
some reports of adverse effects had affected a previous 
measles vaccination campaign in Khyber Pakhtunkhwa.22 
To minimise the risk of problems, we recruited 
experienced vaccinators from the public sector and 
provided 5 days of training on standard WHO methods 
for vaccination. Third, maintenance of the vaccine cold 
chain in camps was a challenge; to address this, 
vaccination teams were given adequate volumes of ice 
packs and back-up thermometers. The vaccines used in 
the study had vaccine vial monitors and staff were trained 
in their use. Finally, uniform access and coverage was a 
challenge: 29 (16 in arm A, seven in arm B, and six in 
arm C) of the 387 clusters became inaccessible at 
different times throughout the course of the project due 
to insecurity and imposition of local curfews. The study 
was limited by the fact that coverage estimates were 
largely based on family reports and the relatively lower 
completeness of post-supplementary immunisation 
activity surveys in Karachi.
As per the recommendation of the Global Polio 
Eradication Initiative, IPV should now have been 
introduced into the routine immunisation schedule of all 
countries that were previously using OPV alone.23 This 
decision is now beset with the challenges of a global IPV 
shortage and prioritisation of supply to some countries.24 
Countries such as Pakistan, where the childhood routine 
immunisation coverage is low among some high-risk 
populations, need to identify strategies to maximise 
coverage with OPV and IPV. Our experience indicates 
that this can be done through short-term camps linked to 
supplementary immunisation activities. However, this 
provision comes at a higher cost and with additional 
needs for human resources, training, and monitoring 
than routine immunisation services require, and should 
not be considered a substitute for such services. 
Nevertheless, in conflict zones and areas with high levels 
of insecurity where access might be an issue, this could 
be a pragmatic approach for achieving rapid coverage of 
routine immunisation and IPV, as has also been shown 
in refugee populations at risk of outbreaks.25
Our study is the first randomised trial of a strategy to 
reach at-risk populations in high-risk and insecure 
populations in Karachi and the border areas of Pakistan 
and Afghanistan. The findings are consonant with 
previous approaches to reach similar populations in 
other regions affected by conflict and insecurity.26,27 
Our experience provides objective evidence that it is 
possible to gain community trust and achieve gains in 
immunisation and OPV and IPV coverage using an 
integrated approach, and has implications for 
geographies facing resistance and limited community 
engagement. Polio eradication in Pakistan faces ongoing 
challenges including insurgency, conflict, and security 
issues, and mistrust of OPV and its campaigns. The 
areas of ongoing poliovirus circulation of FATA, Quetta 
block, and upper Sindh are well known. The military 
operation by the Pakistan Army in the high insurgency 
areas of FATA, such as North Waziristan, Khyber Agency, 
and Tirah valley has opened the opportunity to reach 
hitherto inaccessible populations.18 Efforts at polio 
eradication in Pakistan have accelerated rapidly since our 
study and our findings have been made available to 
policymakers developing response strategies in high-risk 
areas. The holistic approach of community mobilisation 
and establishing regular health camps, focusing on 
maternal and child health and immunisation services 
has since been widely implemented in high-risk union 
councils of Karachi, as well as Khyber Pakhtunkhwa and 
FATA and is beginning to yield results.28,29 This approach 
is now being expanded to high-risk areas in Baluchistan 
with persistent poliovirus circulation. This experience 
also has implications for addressing the challenges in the 
three residual pockets of polio globally, which also 
happen to be geographies affected by conflict and 
insecurity.30,31
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